Yunnan Baiyao
Yunnan Baiyao
Yunnan Baiyao Group manufactures and sells traditional Chinese medicine and preparations, personal care products, and native herbs.
Yunnan Baiyao, founded in November, 1993 and headquartered in Kunming, is a pharmaceutical and health enterprise. The founder is Chen Fashu. Listed on the SZSE on December 15, 1993, the company's major shareholders are Yunnan State-owned Assets Supervision and Administration Commission, Xinhuadu Industrial Group Co., Ltd., Jiangsu Yuyue Technology Development Co., Ltd.. Rivals that have direct and indirect competition with Yunnan Baiyao include Harbin Pharmaceutical, Tongrentang, Glaxo Smith Kline, Pfizer, etc.
- All
- News
- Analysis
- Research
Briefing May 13, 2021 06:43 PM
· Healthcare
HealthTech Miaoshou Doctor (Tencent Investment) ahead of IPO
Briefing Apr 30, 2021 04:35 PM
· Healthcare
Baiji Shenzhou zebutinib CLL / SLL head to head phase III study reached the main end point
In depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Briefing Mar 24, 2021 05:40 PM
· Healthcare
Cancer cell therapy company raised CNY 500 million in D round
Briefing Mar 01, 2021 11:55 AM
· Healthcare
Baiji Shenzhou PD-1 inhibitor price dropped by 80%
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Consumer Discretionary, Real Estate, Consumer StaplesTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Consumer Discretionary, Consumer Staples, Real EstateLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Feb 05, 2021 02:07 PM
· Healthcare
Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
Briefing Feb 01, 2021 02:41 PM
· Healthcare
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Briefing Jan 07, 2021 04:13 PM
· Healthcare
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Briefing Dec 31, 2020 10:20 AM
· Healthcare
Sinopharm new coronavirus vaccine approved
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Healthcare
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Briefing Dec 28, 2020 03:13 PM
· Healthcare
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Briefing Dec 28, 2020 02:44 PM
· Healthcare
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
In depth
Healthcare
Yunnan Baiyao: An Oriental Mystery in the Limelight (2/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:30 PM
In depth
Healthcare
Yunnan Baiyao: An Oriental Mystery in the Limelight (1/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:00 PM
Briefing Dec 23, 2020 11:21 AM
· Healthcare
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Briefing Dec 20, 2020 02:22 PM
· Healthcare
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
Briefing Dec 16, 2020 02:27 PM
· Healthcare
Cell and gene therapy cro / cdmo xuanming cells completed a round of financing, led by Huagai capital and juming venture capital
Briefing Dec 02, 2020 11:21 AM
· Healthcare
Improving service quality and enabling industrial innovation!
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.